Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Completed · Phase 3

Conditions studied: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia

In brief

This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.

Key facts

Study ID

NCT01002222

Run by

Health Ever Bio-Tech Co., Ltd.

People needed

200

Starts

2011-01-01

Expected to finish

2014-02-01

Last updated by the study team

2015-03-03

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Subject has completed 12 weeks of treatment under the protocol MCS-2-US-a.
• Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study.

You may not qualify if…

• Subject has severe LUTS at the last visit under the protocol MCS-2-US-a.
• Subject is considered ineligible for the study by the investigator(s).

Where it is running

• David Geffen School of Medicine at UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.